Connect with us

Technology

Zimmer Biomet Showcases Latest Innovations Across Comprehensive Portfolio at AAOS 2024 Annual Meeting

Published

on

— Booth Highlights Include Persona® OsseoTi® Keel Tibia, a Preview of ROSA® Shoulder*, Pending 510(k) Clearance, and the HAMMR™ Automatic Hip Impaction System–

WARSAW, Ind., Feb. 12, 2024 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is showcasing the latest innovations across its product portfolio at the 2024 annual meeting of the American Academy of Orthopaedic Surgeons (AAOS) this week in San Francisco. During the meeting, the company will display its forthcoming ROSA® Robotics application for shoulder replacement,* which is pending 510(k) clearance, and provide hands-on demonstrations of key growth drivers including Persona® OsseoTi® Keel Tibia for cementless knee replacement, ROSA® Robotics (ROSA Knee and ROSA Hip), Ambulatory Surgery Center (ASC) Solutions, as well as recently launched surgical tools including HAMMR™ Automatic Hip Impaction System, and the ViVi® Surgical Helmet System.

“Every year, the annual AAOS meeting gives us an opportunity to not only demonstrate the breadth and diversity of our portfolio, but also shine a spotlight on the bold and meaningful innovations that transform clinical care, improve the surgical experience, and give us a differentiated competitive advantage,” said Mark Bezjak, President of the Americas at Zimmer Biomet. “From our cementless construct, Persona OsseoTi Keel Tibia, to our ROSA Robotics platform powered by ZBEdge™ Dynamic Intelligence™, we’re excited to share our customer-centric solutions with surgeons from around the world.”

Here are the highlights at the Zimmer Biomet booth (#1127):  

Best-in-Class ImplantsPersona® OsseoTi® Keel Tibia for cementless knee replacement: Launched in 2023, this cementless construct offers stable*1 initial and biological fixation with OsseoTi® porous keel design, versatility to switch between cemented and cementless approach intra-operatively, and an anatomic design for proper rotation and optimal bone coverage.Surgical ToolsHAMMR™ Automatic Hip Impaction System for bone preparation and implant placement during hip replacement surgery: Designed to deliver consistent and controlled energy2 to address surgeon strain, fatigue and repetitive motion associated with a traditional mallet.ViVi® Surgical Helmet System that keeps clinicians cool and comfortable, while providing clear visibility for precise surgical procedures. Illuminated by a powerful 100,000 Lux LED light, ViVi is the quietest3 and most lightweight4,5 surgical helmet available†.Robotics and Data Intelligence ROSA® Robotics: Comprehensive, multi-application platform for knee and hip procedures. Designed for Zimmer Biomet’s leading implants and data technologies, ROSA Robotics redefines robotics by providing real-time insights with the goal to optimize outcomes and revolutionize the standard of care.ZBEdge™ Dynamic Intelligence™: Elevates and unlocks the full potential of Zimmer Biomet’s cutting-edge digital, robotic and implant solutions. ZBEdge technologies collect objective data before, during and after surgery, and then deliver actionable insights to help surgeons make the most informed decision possible.

In addition, the company will provide updates on its ASC strategy, partnerships and comprehensive portfolio. For more information about Zimmer Biomet events at AAOS 2024, visit http://www.zimmerbiomet.com/academy2024

About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X / Twitter at www.twitter.com/zimmerbiomet.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “aims,” “anticipates,” “plans,” “looking forward to,” “estimates,” “projects,” “assumes,” “guides,” “targets,” “forecasts,” “continue,” “seeks” or the negatives of such terms or other variations on such terms or comparable terminology. Forward-looking statements include, but are not limited to, statements concerning the Company’s expectations, plans, intentions, strategies, prospects, business plans, product and service offerings, new product launches, potential clinical successes, and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially. Some of these risks and uncertainties can be found in Zimmer Biomet’s Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent periodic reports filed with the Securities and Exchange Commission (SEC). Copies of these filings are available online at www.sec.govwww.zimmerbiomet.com or on request from the Company. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in the Company’s filings with the SEC. Such forward-looking statements speak only as of the date made, and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this press release are cautioned not to place undue reliance on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this press release.

References

* ROSA Shoulder is currently pending 510(k) clearance and is not commercially available.
† Versus market-share leaders
* Laboratory testing may not be indicative of clinical results.
1 Mueller J.K., et al. Persona OsseoTi Keel Tibia Provides Stable Initial Fixation 4027.2-GLBL-en. November 2022. Laboratory testing may not be indicative of clinical results.
2 Data on File at Zimmer Biomet. Zimmer HAMMR Verification Test Report. DOC0179677. Pages 47-49. January 19, 2024.
3 MD 7.6.3 – TR_ViVi Noise_Competitor Analysis_Rev.01. Page 2. August 24, 2023. Data on file at Zimmer Biomet.
4 THI Airflow-Weight-Light-Noise Summary Report ENG. Page 8. May 31, 2023. Data on file at Zimmer Biomet.
5 THI – Weight – Noise – FOV file. Page 3. September 26, 2023. Data on file at Zimmer Biomet.

Media

Investors

Heather Zoumas-Lubeski

Zach Weiner

445-248-0577

908-591-6955

heather.zoumaslubeski@zimmerbiomet.com

zach.weiner@zimmerbiomet.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-showcases-latest-innovations-across-comprehensive-portfolio-at-aaos-2024-annual-meeting-302059155.html

SOURCE Zimmer Biomet Holdings, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

BRIDGE Appoints Morgan Jetto As Executive Vice President, Business Development & Ecosystems

Published

on

By

Industry Veteran to Lead Strategic Partnerships as BRIDGE Extends Its Position as the Trusted Partner for Audience Targeting, Curation, and Agentic Audience Targeting

NEW YORK, Apr. 21, 2026 /PRNewswire/ — BRIDGE, the verified people-data layer for advertising and marketing, today announced the appointment of Morgan Jetto as Executive Vice President, Business Development & Ecosystems. In this newly created role, Jetto will drive BRIDGE’s partnership strategy, expand its ecosystem of data and media integrations, and accelerate revenue growth across its key growth verticals as demand for verified data surges.

“Morgan brings a rare combination of deep industry relationships, strategic vision, and hands-on execution,” said Robert Rose, CEO of BRIDGE. “The industry is moving toward verified identity, curated audiences advertisers can trust, and agentic audience targeting that needs real, consent-audited people data underneath it. BRIDGE sits at the center of all three shifts, and Morgan’s leadership will help us extend that foundation to every agency, platform, and AI builder who needs it.”

Jetto joins BRIDGE from Verve Group, where he served as Senior Vice President and General Manager. His career spans nearly two decades of proven senior roles in AdTech and MarTech — including global partnerships at Yahoo, client leadership at GroupM, as well as board and advisory roles — with a consistent focus on building partnerships at the intersection of data, media, and emerging technology.

“BRIDGE has built something genuinely differentiated — a verified, people-based data foundation the industry urgently needs, and an architecture built for the next generation of agentic audience targeting,” said Jetto. “I’m excited to join at this critical and pivotal moment and help expand the ecosystem of partners, platforms, and clients who can benefit from the differentiated foundation BRIDGE has built— and I’m just getting started.”

BRIDGE is the verified people-data layer for advertising and marketing — the trusted foundation agencies, brands, platforms, and AI builders rely on for audience targeting and curation. Every record is a real person, verified through the Data Safe™ methodology. The CONNECT platform activates the same verified person across CTV, digital, social, email, audio, programmatic, and direct mail, and is built for agentic audience targeting through Connect MCP. People Match™ closes the loop with deterministic attribution. BRIDGE powers 160,000+ campaigns annually and has been ranked #1 for data accuracy by Truthset — an independent third party — for five consecutive years. The graph includes 412.9M verified consumers and business people and 679.8M permission-based emails, anchored on SOC2, SOC3, and HIPAA compliance. Learn more at www.thebridgecorp.com.

Media Contact

Karen Nordahl
BRIDGE
Director, Human Resources 
connect@thebridgecorp.com
+1 ( 212) 991-5633

View original content to download multimedia:https://www.prnewswire.com/news-releases/bridge-appoints-morgan-jetto-as-executive-vice-president-business-development–ecosystems-302749323.html

SOURCE BRIDGE

Continue Reading

Technology

SOLOWIN HOLDINGS Expects Revenue in the Range of $27 Million to $29 Million, Approximately 10x Year-over-Year Growth for the Fiscal Year Ended March 31, 2026 Based on Preliminary Unaudited Results

Published

on

By

HONG KONG, April 21, 2026 /PRNewswire/ — SOLOWIN HOLDINGS (Nasdaq: AXG) (“SOLOWIN,” the “Company,” or “we”), a leading financial technology firm bridging traditional and digital assets, today announced certain preliminary, unaudited financial results for the fiscal year ended March 31, 2026. Driven by the rapid expansion of its digital asset tokenization, stablecoin infrastructure, and AI-powered services, the Company delivered exceptional top-line growth for the fiscal year ended March 31, 2026, as it advances its global framework compliance and institutional-grade service strategy.

The preliminary financial results described in this press release are unaudited and based on management’s current estimates of our results for the fiscal year ended March 31, 2026. These figures are subject to the completion of our customary year-end financial closing procedures and audit by the Company’s independent registered public accounting firm. No assurance can be given that final audited results will not differ materially from these preliminary estimates, and any such differences could be significant. We expect to file our audited financial results for the fiscal year ended March 31, 2026, with the U.S. Securities and Exchange Commission in our Annual Report on Form 20-F, which is expected to be filed in July 2026.

Overall Performance

Revenue increased nearly tenfold year over year to between $27 million and $29 million for the fiscal year ended March 31, 2026.

Net loss was in the range of $11 million to $13 million, reflecting continued investment in technology, compliance, and global business expansion.

Financial Condition

As of March 31, 2026, cash and cash equivalents increased to between $14 million and $16 million.

Net cash used in operating activities was in the range of $12 million to $14 million for the year ended March 31, 2026. The increase in receivables from customers was the primary driver of the cash used in operating activities during the current period.

Net cash provided by investing activities was in the range of $1 million to $3 million for the year ended March 31, 2026, mainly consisting of cash and bank balances arising from acquisition of subsidiaries, partly offset by purchases of short-term investments.

Net cash provided by financing activities increased to between $18 million and $20 million for the year ended March 31, 2026, mainly representing the proceeds from capital injections from investors.

Strategic Overview

Against a backdrop of accelerating institutional adoption, maturing global regulation, and deepening integration of AI and blockchain, SOLOWIN has further consolidated its position as a fully compliant, vertically integrated digital financial platform, with a clear dual-token strategy focused on Digital Asset Tokens and AI Tokens. The Company’s ecosystem spans stablecoin issuance and payments, asset tokenization, securities trading and asset management, as well as AI-powered services.

Management Commentary

Mr. Lok Ling Ngai, Chief Executive Officer and Chairman of SOLOWIN, stated: “Fiscal 2026 marks a transformative year for SOLOWIN. Achieving tenfold revenue growth represents more than a financial milestone, it validates the strength of our dual-token strategy and underscores the accelerating global demand for compliant, institutional-grade digital asset infrastructure. We are uniquely positioned at the convergence of three structural shifts reshaping our industry: the advancement of regulatory frameworks, the rapid adoption of tokenization, and the integration of AI with blockchain technologies.”

“Guided by our mission ‘Mobilizing Tokens 24/7,’ we are building a secure, efficient, and fully regulated digital financial ecosystem. Over the past year, we have significantly strengthened and expanded our stablecoin and payment infrastructure, scaled our asset tokenization capabilities, and enhanced our AI-powered services. Together, these efforts reinforce and deepen our licensed platform advantages across Hong Kong, Bahrain, and other key global markets.”

“We see ourselves as more than a technology company — we are a trusted bridge connecting traditional finance and the decentralized economy. As global regulatory frameworks continue to mature and institutional adoption accelerates, we remain steadfast in our commitment to compliance, transparency, and responsible innovation. Our goal is to deliver sustainable, long-term value for our clients, partners, and shareholders — and help to power the future of finance.”

About SOLOWIN HOLDINGS

SOLOWIN HOLDINGS (NASDAQ: AXG) is a leading global regulated fintech company. Established in 2016, AXG combines blockchain and artificial intelligence technologies to operate a fully compliant dual-token digital economy super platform.

Guided by the mission “Mobilizing Tokens 24/7,” the Company focuses on tokenization and operates two core business pillars: Digital Asset Tokens and AI Tokens. Its offerings span stablecoin issuance and payments, asset tokenization, securities trading and asset management, as well as AI-powered services including cloud infrastructure, Know-Your-Agent verification, and token router.

Through its integrated ecosystem, including AXCOIN, AXONE, FERION, SOLOMON, SCION, and KOVAR, AXG empowers global institutions and investors to capitalize on the rapid growth of the dual-token economy.

For more information, visit the Company’s website at https://www.alloyx.com or Investor Relations webpage at https://ir.alloyx.com

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. The Company has attempted to identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) including the “Risk Factors” section of the Company’s most recent Annual Report on Form 20-F as well as in its other reports filed or furnished from time to time with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC, which are available for review at www.sec.gov.

For investor and media inquiries please contact:

SOLOWIN HOLDINGS
Investor Relations Department
Email: ir@solowin.io

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

View original content:https://www.prnewswire.com/news-releases/solowin-holdings-expects-revenue-in-the-range-of-27-million-to-29-million-approximately-10x-year-over-year-growth-for-the-fiscal-year-ended-march-31-2026-based-on-preliminary-unaudited-results-302749291.html

SOURCE SOLOWIN HOLDINGS

Continue Reading

Technology

Chemours Announces Dates for First Quarter 2026 Earnings Release and Webcast Conference Call

Published

on

By

WILMINGTON, Del., April 21, 2026 /PRNewswire/ — The Chemours Company (“Chemours” or “the Company”) (NYSE: CC) today announced that the Company expects to issue its first quarter 2026 financial results after market on Tuesday, May 5, 2026.

The Company expects to hold its conference call to discuss its first quarter 2026 financial results at 8:00 a.m. Eastern Time on Wednesday, May 6, 2026. The call is open to the public and can be accessed via the webcast information below. The webcast and materials can be accessed by visiting the “Events and Presentations” section of the Investor Relations section of Chemours’ website at investors.chemours.com.

Conference Call: Please visit investors.chemours.com for a link to the live webcast and to view the accompanying slides.

Replay: A webcast replay will be available at investors.chemours.com.

About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers’ biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn

CONTACTS:

INVESTORS
Brandon Ontjes
Vice President, Head of Strategy & Investor Relations
+1.302.773.3300
investor@chemours.com

NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
media@chemours.com  

View original content to download multimedia:https://www.prnewswire.com/news-releases/chemours-announces-dates-for-first-quarter-2026-earnings-release-and-webcast-conference-call-302749283.html

SOURCE The Chemours Company

Continue Reading

Trending